RxDoctor Payments Data

Gary McCulloch, MD

Family Medicine · Eclectic, ALNPI 1568410181

Payments from drug & device makers

$555in general payments, 2019–2025

Across 31 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$238
  • Astellas Pharma US Inc$89
  • Pfizer$46
  • Amarin Pharma, Inc.$45
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$34
  • Orthogenrx Inc.$20
  • plus $82 from 5 others

What the payments were for

  • Food & beverage$46684%
  • Education$8916%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$555 in reported general payments places this provider in the 45th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$112,805
Medicare patients
229
Services billed
2,554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$74,258
EliquisApixaban72$68,444
FarxigaDapagliflozin Propanediol42$53,327
JardianceEmpagliflozin45$42,643
XareltoRivaroxaban40$29,295
MounjaroTirzepatide29$25,787
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$24,882
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$22,562
RybelsusSemaglutide11$21,894
TrulicityDulaglutide23$21,359
LinzessLinaclotide34$20,037
MyrbetriqMirabegron19$12,700
Bydureon BciseExenatide Microspheres13$11,810
DuleraMometasone/Formoterol16$8,074
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$7,998

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$14$96,15179 claims
AstraZenecaFarxiga, Breztri Aerosphere$238$78,20976 claims
PfizerEliquis, Premarin$46$72,44786 claims
Lilly USA, LLCMounjaro, Trulicity$17$47,14652 claims
Astellas Pharma US IncMyrbetriq$89$12,70019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Eclectic

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →